Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

By sjmartinez • September 19, 2023

VanderWalde A, Bellasea SL, Kendra KL, Khushalani NI, Campbell KM, Scumpia PO, Kuklinski LF, Collichio F, Sosman JA, Ikeguchi A, Victor AI, Truong TG, Chmielowski B, Portnoy DC, Chen Y, Margolin K, Bane C, Dasanu CA, Johnson DB, Eroglu Z, Chandra S, Medina E, Gonzalez CR, Baselga-Carretero I, Vega-Crespo A, Garcilazo IP, Sharon E, Hu-Lieskovan S, Patel SP, Grossmann KF, Moon J, Wu MC, Ribas A. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nat Med. 2023 Sep;29(9):2278-2285. doi: 10.1038/s41591-023-02498-y. Epub 2023 Aug 17. PMID: 37592104.

Tags: Dermatology, Hematology/Oncology, Publications

BayesAge 2.0: a maximum likelihood algorithm to predict transcriptomic age

Mboning L, Costa EK, Chen J, Bouchard LS, Pellegrini M. BayesAge 2.0: a maximum likelihood algorithm to predict transcriptomic age. Geroscience. 2025 Jan 3. doi:[...]

Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review

Kakani P, Davis J. Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review. Skinmed. 2024 Dec 31;22(6):422-426. PMID: 39748573.

An evaluation framework for clinical use of large language models in patient interaction tasks

Johri S, Jeong J, Tran BA, Schlessinger DI, Wongvibulsin S, Barnes LA, Zhou HY, Cai ZR, Van Allen EM, Kim D, Daneshjou R, Rajpurkar P.[...]